We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed, Inc. reported second-quarter fiscal 2019 earnings per share of 81 cents, which surpassed the Zacks Consensus Estimate by 11%. Adjusted earnings skyrocketed 84.1% from the year-ago quarter.
Revenues in the reported quarter came in at $181.8 million, outpacing the Zacks Consensus Estimate of $175.3 million. Revenues also improved 36.9% from the prior-year quarter.
Meanwhile, the Zacks Rank #1 (Strong Buy) stock has rallied 98.3% compared with the industry’s 17.8% in a year’s time. The current level is also higher than the S&P 500 index’s rise of 6.4%.
Per management, U.S. revenues rose 33% year over year to $158 million, driven by a 29% increase in overall patient utilization in the second quarter. Outside the United States, revenues were $24 million, up 67% from the year-ago quarter.
European revenues increased 38%, with German revenues up 33% year over year.
Additionally, the company recorded revenues of $4.1 million in Japan.
Impella Sustains Momentum
Abiomed’s flagship Impella heart pump revenues totaled $175.3 million in the second quarter, globally. Per management, this shows a year-over-year upside of 38%.
U.S. Impella heart pump revenues totaled $152.2 million in the reported quarter, reflecting an increase of 34% from the prior-year quarter.
Outside the United States, Impella heart pump revenues totaled $23.1 million, up 67%.
Furthermore, the Impella 2.5 and CP were placed at approximately 1,250 sites in the United States by the end of the reported quarter. Additionally, the Impella 5.0 and RP were placed at 559 and 368 sites, respectively.
Margin Trend
In the quarter under review, gross margin was 83.6%, down 10 basis points (bps) year over year. Per management, the benefit from higher volume was offset by manufacturing investments such as direct labor hires to support growth.
Research & Development (R&D) costs in the second quarter grossed $22.7 million, up 17.2% year over year.
Operating income in the quarter totaled $50.3 million, up 58.6% on a year-over-year basis. Operating margin was 27.7%, up 380 bps.
Financial Condition
Abiomed’s cash and marketable securities for the fiscal second quarter were $410.4 million. The company currently has no debt.
FY19 Outlook
Abiomed raised its fiscal 2019 guidance.
For fiscal 2019, the company expects revenues in the band of $765-$770 million, showing an increase of 29-30% from the previous fiscal. This compares to the earlier guidance of $755-$770 million, showing a year-over-year rise of 27-30%.
Notably, the Zacks Consensus Estimate is pegged at $768.2 million, within the guided range.
Abiomed expects to see strong contribution from its core Impella product lines in the quarters ahead.
Summing Up
Abiomed wrapped up the second quarter of fiscal 2019 on a solid note. The company continues to gain from its flagship Impella which saw a strong quarter in the United States. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan shot up in the quarter.
Raised guidance for fiscal 2019 is indicative of brighter prospects. Considerable expansion in the operating margin also buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. Abiomed’s balance sheet remains debt free.
However, contraction in the company’s gross margin raises concern. Intense competition in the industry is likely to mar prospects. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.
Intuitive Surgical reported third-quarter 2018 adjusted earnings per share of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, also surpassing the consensus estimate of $918.6 million.
Stryker posted third-quarter 2018 adjusted earnings per share of $1.69, steering past the Zacks Consensus Estimate by a penny. Operating margin was 17.8%, up 30 bps.
Merit Medical reported third-quarter 2018 adjusted earnings per share of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus estimate of $218 million.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Abiomed (ABMD) Q2 Earnings Beat, Impella Maintains Momentum
Abiomed, Inc. reported second-quarter fiscal 2019 earnings per share of 81 cents, which surpassed the Zacks Consensus Estimate by 11%. Adjusted earnings skyrocketed 84.1% from the year-ago quarter.
Revenues in the reported quarter came in at $181.8 million, outpacing the Zacks Consensus Estimate of $175.3 million. Revenues also improved 36.9% from the prior-year quarter.
Meanwhile, the Zacks Rank #1 (Strong Buy) stock has rallied 98.3% compared with the industry’s 17.8% in a year’s time. The current level is also higher than the S&P 500 index’s rise of 6.4%.
ABIOMED, Inc. Price, Consensus and EPS Surprise
ABIOMED, Inc. Price, Consensus and EPS Surprise | ABIOMED, Inc. Quote
Q2 in Detail
Geographic Analysis
Per management, U.S. revenues rose 33% year over year to $158 million, driven by a 29% increase in overall patient utilization in the second quarter. Outside the United States, revenues were $24 million, up 67% from the year-ago quarter.
European revenues increased 38%, with German revenues up 33% year over year.
Additionally, the company recorded revenues of $4.1 million in Japan.
Impella Sustains Momentum
Abiomed’s flagship Impella heart pump revenues totaled $175.3 million in the second quarter, globally. Per management, this shows a year-over-year upside of 38%.
U.S. Impella heart pump revenues totaled $152.2 million in the reported quarter, reflecting an increase of 34% from the prior-year quarter.
Outside the United States, Impella heart pump revenues totaled $23.1 million, up 67%.
Furthermore, the Impella 2.5 and CP were placed at approximately 1,250 sites in the United States by the end of the reported quarter. Additionally, the Impella 5.0 and RP were placed at 559 and 368 sites, respectively.
Margin Trend
In the quarter under review, gross margin was 83.6%, down 10 basis points (bps) year over year. Per management, the benefit from higher volume was offset by manufacturing investments such as direct labor hires to support growth.
Research & Development (R&D) costs in the second quarter grossed $22.7 million, up 17.2% year over year.
Operating income in the quarter totaled $50.3 million, up 58.6% on a year-over-year basis. Operating margin was 27.7%, up 380 bps.
Financial Condition
Abiomed’s cash and marketable securities for the fiscal second quarter were $410.4 million. The company currently has no debt.
FY19 Outlook
Abiomed raised its fiscal 2019 guidance.
For fiscal 2019, the company expects revenues in the band of $765-$770 million, showing an increase of 29-30% from the previous fiscal. This compares to the earlier guidance of $755-$770 million, showing a year-over-year rise of 27-30%.
Notably, the Zacks Consensus Estimate is pegged at $768.2 million, within the guided range.
Abiomed expects to see strong contribution from its core Impella product lines in the quarters ahead.
Summing Up
Abiomed wrapped up the second quarter of fiscal 2019 on a solid note. The company continues to gain from its flagship Impella which saw a strong quarter in the United States. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan shot up in the quarter.
Raised guidance for fiscal 2019 is indicative of brighter prospects. Considerable expansion in the operating margin also buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. Abiomed’s balance sheet remains debt free.
However, contraction in the company’s gross margin raises concern. Intense competition in the industry is likely to mar prospects. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.
Earnings of Other MedTech Majors at a Glance
Other top-ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical (ISRG - Free Report) , Stryker Corp. (SYK - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) . Each of the stocks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported third-quarter 2018 adjusted earnings per share of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, also surpassing the consensus estimate of $918.6 million.
Stryker posted third-quarter 2018 adjusted earnings per share of $1.69, steering past the Zacks Consensus Estimate by a penny. Operating margin was 17.8%, up 30 bps.
Merit Medical reported third-quarter 2018 adjusted earnings per share of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus estimate of $218 million.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>